In this study we were able to gain knowledge in the comparison of safety profiles of PD-L1 inhibitors monotherapy as 1L treatment of advanced NSCLC patients versus chemotherapy, and to underpin differences between anti-PD-1 and anti-PD-L1 immunotherapy agents, nevertheless, our NMA also has some limitations. Here, CD274 is linked to non-small cell lung carcinoma.